Department of Surgical Gastroenterology L, Aarhus University Hospital, Aarhus, Denmark.
N Engl J Med. 2011 Oct 13;365(15):1375-83. doi: 10.1056/NEJMoa1103042.
Accurate population-based data are needed on the incidence of esophageal adenocarcinoma and high-grade dysplasia among patients with Barrett's esophagus.
We conducted a nationwide, population-based, cohort study involving all patients with Barrett's esophagus in Denmark during the period from 1992 through 2009, using data from the Danish Pathology Registry and the Danish Cancer Registry. We determined the incidence rates (numbers of cases per 1000 person-years) of adenocarcinoma and high-grade dysplasia. As a measure of relative risk, standardized incidence ratios were calculated with the use of national cancer rates in Denmark during the study period.
We identified 11,028 patients with Barrett's esophagus and analyzed their data for a median of 5.2 years. Within the first year after the index endoscopy, 131 new cases of adenocarcinoma were diagnosed. During subsequent years, 66 new adenocarcinomas were detected, yielding an incidence rate for adenocarcinoma of 1.2 cases per 1000 person-years (95% confidence interval [CI], 0.9 to 1.5). As compared with the risk in the general population, the relative risk of adenocarcinoma among patients with Barrett's esophagus was 11.3 (95% CI, 8.8 to 14.4). The annual risk of esophageal adenocarcinoma was 0.12% (95% CI, 0.09 to 0.15). Detection of low-grade dysplasia on the index endoscopy was associated with an incidence rate for adenocarcinoma of 5.1 cases per 1000 person-years. In contrast, the incidence rate among patients without dysplasia was 1.0 case per 1000 person-years. Risk estimates for patients with high-grade dysplasia were slightly higher.
Barrett's esophagus is a strong risk factor for esophageal adenocarcinoma, but the absolute annual risk, 0.12%, is much lower than the assumed risk of 0.5%, which is the basis for current surveillance guidelines. Data from the current study call into question the rationale for ongoing surveillance in patients who have Barrett's esophagus without dysplasia. (Funded by the Clinical Institute, University of Aarhus, Aarhus, Denmark.).
需要基于人群的准确数据来了解巴雷特食管患者中食管腺癌和高级别异型增生的发病率。
我们进行了一项全国性的基于人群的队列研究,纳入了丹麦在 1992 年至 2009 年期间所有的巴雷特食管患者,研究数据来自丹麦病理登记处和丹麦癌症登记处。我们计算了腺癌和高级别异型增生的发病率(每 1000 人年的病例数)。采用研究期间丹麦全国癌症发病率作为相对风险的衡量指标,计算了标准化发病率比。
我们共确定了 11028 例巴雷特食管患者,对其数据进行了中位数为 5.2 年的分析。在索引内镜检查后的第一年,诊断出 131 例新的腺癌病例。随后的几年中,又检测到 66 例新的腺癌病例,腺癌的发病率为 1.2 例/1000 人年(95%置信区间 [CI],0.9 至 1.5)。与普通人群相比,巴雷特食管患者患腺癌的相对风险为 11.3(95%CI,8.8 至 14.4)。食管腺癌的年发病风险为 0.12%(95%CI,0.09 至 0.15)。索引内镜检查发现低级别异型增生与腺癌的发病率为 5.1 例/1000 人年相关。相比之下,无异型增生患者的发病率为 1.0 例/1000 人年。高级别异型增生患者的风险估计值略高。
巴雷特食管是食管腺癌的一个强有力的危险因素,但绝对年发病风险为 0.12%,远低于当前监测指南所假设的 0.5%的风险。本研究的数据对目前无异型增生的巴雷特食管患者是否需要进行持续性监测提出了质疑。(由丹麦奥胡斯大学临床研究所提供资金支持)。